Interesting article on GT and pharma, page-4

Another good article Hoy
Did you read the link in the article http://articles.philly.com/2015-04-08/news/60907212_1_penn-and-novartis-carl-june-immunotherapy. I feel this maybe a future issue for us. The Graham patents are in later stages of protection and our newer ones are based on the specific results. If as your article suggests small labs can cost effectively produce treatments then we will have a very busy time trying to put out bush fires. We just have to get there first with the single shot treatment. From discussions I had at the AGM some of our issues are very human related and a reflection that we are not a large company that can afford the screening of an excess of patients prior to dosing. The next few months will set our direction.